JPMorgan raised the firm’s price target on Edgewise Therapeutics to $30 from $27 and keeps an Overweight rating on the shares following a model update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EWTX:
- TipRanks ‘Perfect 10’ List: 3 Stocks that Analysts Rate a Strong Buy
- Edgewise Therapeutics added to Best Ideas List at Wedbush
- Edgewise Therapeutics participates in a conference call with JPMorgan
- Edgewise Therapeutics management to meet with Piper Sandler
- Edgewise Therapeutics initiated with Not Rated at Goldman Sachs